CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 453 enrolled
Drug / intervention
CD5789 (trifarotene)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02189629
NCT02189629Phase 3Completed
CompareCT.gov

A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS

Galderma R&D·interventional·Posted Jul 14, 2014·Updated Nov 14, 2019

In Brief

A Phase 3 clinical trial evaluating CD5789 (trifarotene) for Acne Vulgaris. Completed, enrolled 453 participants across 32 sites in 4 countries.

Detailed Summary

Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesCzechia, Germany, Hungary, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 14, 2014
Enrollment StartFeb 23, 2015
Primary CompletionFeb 23, 2017
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.0 years ago

Interventions

CD5789 (trifarotene)drug